Docking Studies on Novel Drugs Against Drug Re- sistant Tuberculosis

he resurgence of drug resistant tuberculosis and HIV associated intractable mycobacterial infection are of serious global concern. This is due to their potential to survive dormantly in a nonreplicating state in protective intracellular niches of Macrophages, dendritic cells, epithelial cells, endothelial cells, fibrocytes, adipocytes and bone marrow stem cells. To contain this situation, new antituberculosis drugs and reduced regimen treatments are of immediate requirement as envisaged by WHO. Development of novel anti-tuberculosis compounds to combat drug resistant tuberculosis is urgently needed. The discovery of new drugs involves several constraints that discourage many companies from investing in new antituberculosis drugs. The research is expensive, slow and difficult, and it requires specialized facilities for handling Mycobacterium tuberculosis (MTB). Due to this situation, it is a matter of urgency to develop new anti-tuberculous drugs, especially with the aid of bioinformaticsbased drug design, in order to tackle intractable tuberculosis.